Overview
HPV DNA tests detect nucleic acids of designated high-risk HPV genotypes, sometimes with partial genotyping (e.g., 16/18).
Clinical Importance
Primary cervical screening or co-testing with cytology per guideline pathways
Triage of abnormal cytology in selected algorithms
Specimen Requirements
- Specimen: cervical specimen in validated liquid-based cytology medium or dedicated HPV collection kit
- Collection: clinician-collected preferred for many screening programs; follow local self-collection validation if used
- Handling: observe medium stability limits
Analytical Method
Target amplification or signal-amplification NAAT methods detect hrHPV DNA/RNA per IFU. Genotyping channels identify HPV 16/18 when included. Results integrate with cytology and age-based screening guidelines; not interpreted in isolation.
Instruments Used
Automated analyzers
- Hologic Aptima / Panther HPV assays
- Roche Cobas HPV systems
- Other validated hrHPV platforms
Manual methods
- Laboratory-developed HPV PCR in specialized settings
Reference Values
Molecular cutoffs, units (IU/mL, copies/mL, Ct), reportable ranges, and variant classifications are assay- and laboratory-specific. Always interpret against the performing laboratory report, manufacturer IFU, and current CLSI / CAP / AMP / ACMG guidance as adopted locally. Limit of detection and inhibition controls are essential for negative results.
hrHPV not detected / detected (± genotype). Screening cutoffs and follow-up are guideline-defined, not a numeric reference interval.
Interpretation
Common Causes of Increased Results
- hrHPV detected; follow age- and cytology-specific risk algorithms
Common Causes of Decreased Results
- hrHPV not detected; lower immediate CIN3+ risk in validated screening contexts; resume routine intervals per guidelines
Clinical Significance
- Cervical cancer screening programs
Factors Affecting Results
Pre-analytical
- Wrong specimen type or transport medium for the validated assay
- Delayed transport degrading RNA targets
- Contamination during collection (especially amplicon-rich environments)
- Inadequate volume or low cellularity/tumor content
Analytical
- PCR inhibition (heparin, humic acids, excess hemoglobin; assay-dependent)
- Extraction failure or pipetting/contamination in amplification areas
- Probe/primer mismatch with sequence variants causing false negatives
- Calibration/QC failure; expired reagents
Post-analytical
- Reporting Ct or raw copies without assay-specific interpretive rules
- Misapplying another laboratory’s LOD or units
- Variant classification without current ACMG/AMP framework when required
Advantages and Limitations
Advantages
- High sensitivity for underlying high-grade disease risk in screening
Limitations
- Detects infection, not cancer itself
- Specificity lower in younger populations; age matters
Clinical Pearls
HPV DNA positive is a risk signal for algorithms; not a cancer diagnosis stamp.
References
Authoritative textbooks, guidelines, and reviews supporting this laboratory test reference. Verify reference intervals, critical limits, and method details against institutional protocols and current guideline editions.
Textbooks
- McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2021. (Molecular diagnostics chapters, verify current edition.)
- Buckingham L. Molecular Diagnostics: Fundamentals, Methods, and Clinical Applications. 3rd ed. F.A. Davis; 2019. (Verify current edition and institutional adoption.)
CLSI and Professional Guidelines
- Clinical and Laboratory Standards Institute (CLSI). Consult current CLSI molecular method documents available through your laboratory, document numbers and editions change; do not treat any single CLSI title as universal.
- Institutional molecular laboratory standard operating procedures (SOPs), assay manufacturer instructions for use (IFU), and locally adopted accreditation requirements. Always verify current local practice.
- Clinical and Laboratory Standards Institute (CLSI). Molecular method evaluation and related documents (verify current CLSI editions applicable to the assay).
- College of American Pathologists. Molecular pathology accreditation and proficiency testing expectations (verify current CAP checklist requirements).
- Association for Molecular Pathology (AMP). Practice guidelines and position statements for molecular diagnostics (verify current AMP documents for the assay).
- American College of Medical Genetics and Genomics (ACMG). Standards and guidelines for interpretation of sequence variants and related genetic testing practice (verify current ACMG documents).
WHO Publications
- World Health Organization. Laboratory and diagnostic guidance relevant to molecular testing (verify current WHO publication for the assay/pathogen).
Frequently Asked Questions
Common questions about using this HPV DNA Testing laboratory test Medical Laboratory Library reference in Medical Laboratory Science education.
What is the HPV DNA Testing laboratory test reference used for?
This Medical Laboratory Library page summarizes the clinical importance of HPV DNA Testing. Review the Clinical Importance section for why the test is ordered in laboratory medicine practice.
Where can I find HPV DNA Testing specimen requirements?
See the Specimen Requirements section on this page for specimen information related to HPV DNA Testing. Confirm collection details against your laboratory protocol.
Where are HPV DNA Testing reference values listed?
See the Reference Values section on this Laboratory Library page. Reference ranges can vary by method and population, so verify intervals with your laboratory.
How do I interpret HPV DNA Testing results?
Use the Interpretation section for laboratory interpretation framing, including increased and decreased result patterns when provided. Do not treat educational text as a patient-specific diagnosis.
What analytical method is used for HPV DNA Testing?
See the Analytical Method section for principle and method notes. Method details may differ by instrument and institutional SOP.
Are related laboratory tests linked from HPV DNA Testing?
Yes. The Related Laboratory Tests section lists connected references for continued lookup in the Medical Laboratory Library.
How can I continue learning after reading HPV DNA Testing?
Use Continue learning links on this page for related Academy lessons, medical laboratory quizzes, or laboratory case studies when available for this Molecular Diagnostics topic.
What are the clinical pearls for HPV DNA Testing?
See the Clinical Pearls section for concise laboratory practice notes associated with HPV DNA Testing. Apply pearls alongside institutional protocols.
Reading progress
Awards XP once after you have meaningfully reviewed this article.